The Maximum Tolerated Dose was not achieved and SGEN said that dosing schedule and dose escalation continues in this trial: http://www.marketwatch.com/story/seattle-genetics-reports-preliminary-data-from-phase-i-clinical-trial-of-sgn-75-2010-10-11?reflink=MW_news_stmp